Results of a unicenter randomized study of the safety and efficiency of docetaxel chemotherapy before radical prostatectomy in patients with intermediate- and high-risk prostate cancer: An 11.4-year follow-up

Objective. Our retrospective study is aimed to assess safety, pathological response rate, and long-term oncologic outcomes of radical prostatectomy after neoadjuvant chemotherapy for intermediate- to high-risk PCa.

Materials and methods. Forty-four patients were involved in this study, with a 11.4-year follow-up period, on average. We assessed the RPE results in patients with intermediate and high risk of prostate cancer (PSA>10 ng/ml, Gleason score 7 and more, or clinical stage cT2c and more) after weekly treatment with docetaxel (36 mg/m2 for up to 6 cycles, 21 patients) and compared them with those in the second cohort (23 patients) who met oncologic inclusion criteria but received radical prostatectomy only. The long-term oncologic outcomes in both groups of the patients are reported.

Results. Toxicity has been mostly grade 1-2 in intensity and grade 3 and more complication rate does not exceed 10%. A statistically significant of more than 50% reduction in PSA level (pre- vs. post-chemotherapy) was observed in 52.4% cases. During the 11.4-year follow-up period, improvement in cancer-specific survival (CSS) was noted in 90% of patients from the neoadjuvant chemotherapy group, as compared with 60.9% in radical prostatectomy only group. The biochemical recurrence-free survival (BCR) was 68.5 % and 37.7 %, and the overall survival (OS) was 75.5 % and 54.6 % in the combined treatment group and surgery only group, respectively. However, the differences in BCR and OS were not statistically significant.

Conclusion. The use of neoadjuvant chemotherapy represents a safe and practicable treatment strategy resulting in reduced prostate volume and PSA level. Neoadjuvant docetaxel chemotherapy followed by radical prostatectomy was associated with higher observed BCR and OS, as compared with a surgical treatment only group. A statistically significant improvement of CSS is found in the combined treatment group. Therefore, the benefits of this treatment modality need to be validated for feasible implementation in the modern standard practices of prostate cancer treatment.

1. Heidenreich A., Bastian P.J., Bellmunt J. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65(2):467–79.

2. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9–29.

3. Алексеев Б.Я., Нюшко К.М. Адъювантная гормональная терапия как метод радикального лечения у больных местнораспространенным раком предстательной железы. Онкоурология 2007;2: 61–3.

4. Vallett B.S. Radical perineal prostatectomy subsequent to bilateral orchiectomy. Delaware Med J 1944;16:19–20.

5. Dorff T.B., Glode L.M. Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer. Curr Opin Urol 2013;23(4):366–71.

6. Shelley M.D., Kumar S., Wilt T. et al. A systematic review and meta-analysis of randomised trials of neoadjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009;35(1):9–17.

7. McLeod D.G., Iversen P., See W.A. et al. Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97(2):247–54.

8. Mcleod D.G. Hormonal therapy: historical perspective to future directions. Urology 2003;61:3–7.

9. Oh W.K., George D.J., Kaufman D.S. et al. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol 2001;28:40–4.

10. Berger A.P., Niescher M., Fischer-Colbrie R. et al. Single-agent chemotherapy with docetaxel significantly reduces PSA levels in patients with high-grade localized prostate cancers. Urol Int 2004;73(2):110–2.

11. D'Amico A.V., Chen M.H., Roehl K.A., Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. The New England Journal of Medcine 2004;351:125–35.

12. Ross R.W., Galsky M.D., Febbo P. et al. Phase II study of neoadjuvant chemotherapy with docataxel and bevacizumab in patients with high-risk localized prostate cancer: a prostate cancer clinical trials consortium trial. Cancer 2012;118(19):4777 84.

13. Петров С.Б. Хирургия предстательной железы. Спб.: Издательство Сергея Ходова, 2004; с. 179–192.

14. Dindo D., Demartines N., Clavien P.A. Classification of surgical complications. A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–13.

15. Martin II R.C., Brennan M.F., Jaques D.P. Quality of complication reporting in the surgical literature. Ann Surg 2002;235:803–13.

16. Ringel I., Horwitz S.B. Effect of alkaline pH on taxol-microtubule interactions. J Pharmacol Exp Ther 1991;259(2):855–60.

17. Алексеев Б.Я., Нюшко К.М. Комбинированное лечение рака предстательной железы: клинические наблюдения. Онкоурология 2012;4:77–87.

18. Dreicer R., Magi-Galluzzi C., Zhou M. et al. Phase II of neoadjuvant docataxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004;63:1138–42.

19. Febbo P.G., Richie J.P., George D.J. et al. Neoadjuvant docataxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11:5233–40.

20. Eastham J.A., Kelly W.K., Grossfeld G.D., Small E.J. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003;62:55–62.

21. Azulay D.O., Murphy P., Graham J. The accuracy of prostate volume measurement from ultrasound images: a quasi-Monte Carlo simulation study using magnetic resonanse imaging. Comput Med Imaging Graph 2013;7–8:628–35.

22. Civantos F., Marcial M.A., Banks E.R. et al. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer 1995;75(7):1634–41.

23. Bullock M.J., Srigley J.R., Klotz L.H., Goldenberg S.L. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial. Am J Surg Pathol 2002;26(11):1400–13.

24. Smith D.M., Murphy W.M. Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. Cancer 1994;73(5):1472–7.

25. Herkommer K., Kuefer R., Gschwend J.E. et al. Pathological T0 prostate cancer without neoadjuvant therapy: clinical presentation and follow-up. Eur Urol 2004;45:36–41.

26. Soloway M.S. Role of induction androgen deprivation before radical prostatectomy. Semin Urol 1995;13(2):142–7.

27. Köllermann J., Feek U., Müller H. et al. Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma. Eur Urol 2000;38:714–20.

28. Maldonado-Valadez R., Teber D., Erdogru T. et al. The impact of neoadjuvant hormonal therapy on the outcome of laparoscopic radical prostatectomy: a matched pair analysis. J Urol 2006;175(6):2092–6.